Mallia Aesthetics Reports Positive Results from Consumer Study with its Hormone-Free 8T3 Essentials Lash & Brow Serum

- **With a new mode of action, 8T3 Essentials Lash & Brow Serum provides an effective, safe alternative to hormone-containing lash serums that are facing a potential EU ban over safety concerns.**
- **Over 80% of study participants reported longer eyelashes after 12 weeks**
- **After only 4 weeks, 67% of users already saw improvements in lash length**

Erlangen, Germany, April 08, 2026 - Mallia Aesthetics GmbH, a company focusing on the development and commercialization of cosmetic products to stimulate hair growth, today announced positive results from a 12-week consumer study evaluating the performance of its hormone-free topical 8T3 Essentials Lash & Brow Serum. The study demonstrated rapid and visible improvements in eyelash appearance, with the majority of participants reporting longer, stronger, and fuller-looking lashes.

The study included 21 female participants who applied 8T3 Essentials Lash & Brow Serum once daily to their eyelashes for 12 weeks. Users quickly saw improvements: 67% of participants reported longer eyelashes after just 4 weeks of use. After 12 weeks, 81% of participants observed longer or clearly longer eyelashes. Overall, 95% of study participants found the daily application of 8T3 Essentials Lash & Brow Serum to be convenient and easy.

Objective assessments using state-of-the-art standardized imaging technology from Canfield Scientific were used to further evaluate eyelash length, intensity (darkness), and density. The results revealed increases of up to 39% in length and 32% in intensity in individual measurements. Notably, the use of 8T3 Essentials Lash & Brow Serum appears to be particularly beneficial for individuals with initially sparse or thin eyelashes, where users experienced the most noticeable improvements in overall lash appearance. For more information on the study results, click here.

“These results demonstrate the strong performance of our hormone-free eyelash serum. By supporting natural lash growth, 8T3 Essentials Lash & Brow Serum helps consumers achieve their eyelashes’ full individual potential for increased length and volume,” said **Dr. Anne Asmuß, Managing Director of Mallia Aesthetics.** “Consumers today are looking for effective beauty solutions that are also safe and scientifically grounded. Our approach focuses on supporting natural biological pathways to deliver visible results, without the risks of permanent side effects that come with hormone-based lash serums.”

Hormone-based lash serums, which contain synthetic analogues of the hormone prostaglandin, have been associated with a range of side effects, some of them irreversible, including iris discoloration, darkening of the skin around the eyes, orbital fat loss, and eye irritations. Their use in cosmetic products is facing increasing scrutiny. In February 2026, the European Scientific Committee on Consumer Safety (SCCS) concluded that prostaglandin analogues cannot be considered safe for use in cosmetic products aimed at promoting eyelash and eyebrow growth, citing concerns over adverse effects.[1] This means that hormone-based lash serums will likely face regulatory restrictions in Europe in the future.

With 8T3 Essentials Lash & Brow Serum, Mallia offers a safe, hormone-free alternative to fully unlock the natural growth potential of consumers' eyelashes. The product is available via Mallia's webshop.

Benoit Chardon, CEO and Founder of BCC and expert in medical aesthetics, health, and wellness, commented: "Mallia's 8T3 line is built on a novel immuno-biological approach using sCD83-derived technology. This targets regenerative pathways at the hair root, activating follicular stem cells and supporting natural growth processes without hormones or harsh actives. A true step forward for anyone seeking science-led innovation in hair regeneration. I have no doubt this innovation will go far: the guests from our IMCAS networking event who tried Mallia's eyelash treatment have started to share great feedback about the efficacy. This innovation is disrupting hair growth!"

About sCD83

Soluble CD83 (sCD83) is an immunomodulatory protein that is currently being developed for the topical treatment of hair loss (MAL-856) and stimulation of hair growth (MAL-838). The soluble CD83 protein was first identified in 2001 by Mallia co-founder Prof. Steinkasserer. It has anti-inflammatory properties via the induction of resolution of inflammation, which promotes wound healing and induces new hair growth[2]. In addition, sCD83 has been shown to activate regulatory T cells (Tregs)[3], which interact directly with hair follicles and can activate them.[4] Furthermore, sCD83 inhibits cell death of hair follicles and directly activates follicular stem cells, as well as keratin production, thereby stimulating new hair growth. This multimodal mode of action distinguishes sCD83 from other topically applied hair growth agents.

Topically applied, sCD83 can directly reach the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a major advantage over systemic treatment options, which can cause severe side effects.

About hair loss

Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of women post menopause are affected by androgenetic alopecia. Another 147 million people suffer from immune-related, circular hair loss (alopecia areata, or AA[5,6]).

Androgenetic alopecia usually progresses gradually and is due to genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it causes thinning hair in the parting area. Alopecia areata causes circular hair loss on the scalp, face or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss.

About Mallia

Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the proprietary development and commercialization of biopharmaceutical therapies and cosmetic applications of the immunomodulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing.

Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions. MAL-856 is based on the scientifically proven immunomodulatory mode of action of sCD83, which has been investigated for close to 25 years by Mallia Co-founder Prof. Dr Alexander Steinkasserer.[7]

Mallia Aesthetics GmbH focuses on cosmetic applications for the stimulation of hair growth, which are also based on the scientifically validated sCD83 protein. The Company develops Innovative cosmetic products using MAL-838 that are marketed to specialists and consumers.

To purchase products from the 8T3 Essentials line, please visit our online shop: www.8T3.com

For more information, visit www.mallia.com and follow us on LinkedIn, Instagram, and Facebook.

Mallia Contact:
Mallia Innovations GmbH
info@mallia.com

International media contact:
MC Services AG
Dr. Regina Lutz / Katja Arnold
Tel.: +49 (0)89 210 228 0
E-Mail: mallia@mc-services.eu

---

[1] Scientific Committee on Consumer Safety (SCCS). (2026). SCCS - Prostaglandin Analogues: Methylamido-Dihydro-Noralfaprostal (MDN), Isopropyl Cloprostenate (IPCP), Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE). SCCS/1680/25. Available online: https://health.ec.europa.eu/publications/sccs-prostaglandin-analogues-methylamido-dihydro-noralfaprostal-mdn-isopropyl-cloprostenate-ipcp_en

[2] Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., ... & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. *Frontiers in Immunology*, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647

[3] Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., ... & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. *The Journal of Immunology*, *191*(4), 1965-1975. DOI: 10.4049/jimmunol.1201531

[4] Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., ... & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. *Cell*, *169*(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002

[5] Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview

[6] Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., ... & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. *Journal of Managed Care & Specialty Pharmacy*, *28*(4), 426-434: DOI: 10.18553/jmcp.2022.28.4.426

[7] Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., ... & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. *The Journal of experimental medicine*, *194*(12), 1813-1821. DOI: 10.1084/jem.194.12.1813